Cannabidiol and Autonomic Function at Rest

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Cannabidiol (CBD) is one of 700 chemicals derived from the Cannabis sativa plant and is both legal and widespread for distribution in the state of Vermont. The central hypothesis of this proposal is that in apparently healthy adults, acute CBD favorably affects the autonomic nervous system and that this will be evident by an increase in heart rate variability. The overall goal is to understand how CBD affects the autonomic and cardiovascular systems at rest, and when perturbed. The investigators will study a narrow age range of adults, administer varying acute doses of CBD, characterize baseline cardiovascular variables, and record responses to autonomic challenge maneuvers. This will provide the framework to assess potential therapies and/or risk factors of CBD, particularly as it relates to healthy individuals. More information that is so widely taken, especially one that targets receptors known to be involved in cardiovascular signaling pathways is imperative.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Castleton University
• Treatments: Cannabidiol; Epidiolex

Criteria

Inclusion Criteria:

• Male or female, 18-35 years of age.

• Participants must agree to fast and abstain from food or beverages containing alcohol, caffeine, or CBD for 12 hours prior to each experimental session.

• Completion of Health History Questionnaire with report indicating overall good health.

• The ability to comprehend and satisfactorily comply with protocol requirements.

• Written informed consent given prior to beginning the study.

Exclusion Criteria:

• Current medications that might influence the cardiovascular and/or autonomic systems.

• Women who are pregnant or lactating.

• Participants who have a history of adverse reactions to cannabidiol will be excluded.